

**DRUG PRIOR AUTHORIZATION COMMITTEE**

**September 15, 2016**

**TENTATIVE AGENDA**

Department of Natural Resources  
1101 Riverside Dr.  
Lacharette/Nightengale Rooms  
Jefferson City, MO

10:00 - 10:05	Welcome, Announcements and Introductions	Chairman
10:05 - 10:15	Minutes Review	Discussion/Approval
10:15 - 10:25	Pharmacy Program/ Budget Update - Steve Calloway/Christine Thompson	
10:25 - 10:35	DUR Update	Steve Calloway

**Old Business**

10:35 – 10:45	<b>A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)</b>	Steve Calloway
---------------	--	----------------

**New Business**

10:45 – 11:30	<b>B. Proposed Actions - New Drug/Product Review</b> (See website and Attached Summary) <ul style="list-style-type: none"><li><b>i. Open Access</b></li><li><b>ii. Clinical Edit/Step Therapy</b></li><li><b>iii. PDL Products</b></li><li><b>iv. Prior Authorization</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li></ul>	Steve Calloway
---------------	--	----------------

11:30 – 11:45	<b>C. <u>Clinical Edits</u></b> <ul style="list-style-type: none"><li><b>I. Short-Acting Narcotics Clinical Edit</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li><li><b>II. Short-Acting Combination Narcotics Clinical Edit</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li><li><b>III. Opiate Reversal Agents Clinical Edit</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li></ul>	
---------------	---	--

**D. Preferred Drug List (PDL)**

- I. ACE Inhibitor Agents**
  - Discussion
  - Public Hearing
  - Decision
- II. ACE Inhibitors/Calcium Channel Blocker Combination Agents**
  - Discussion
  - Public Hearing
  - Decision
- III. ACE Inhibitors/Diuretic Combination Agents**
  - Discussion
  - Public Hearing
  - Decision
- IV. Angiotensin Receptor Blocker Agents (ARB's)**
  - Discussion
  - Public Hearing
  - Decision
- V. Angiotensin Receptor Blocker/Diuretic Combination Agents**
  - Discussion
  - Public Hearing
  - Decision
- VI. Angiotensin Receptor/Calcium Channel Blocker Combination Agents**
  - Discussion
  - Public Hearing
  - Decision
- VII. Anticoagulant Agents: Oral and Subcutaneous**
  - Discussion
  - Public Hearing
  - Decision
- VIII. Antiplatelet Agents**
  - Discussion
  - Public Hearing
  - Decision
- IX. Beta Adrenergic Blockers and Diuretic Combination Agents**
  - Discussion
  - Public Hearing
  - Decision
- X. Calcium Channel Blocker Agents (Dihydropyridines)**
  - Discussion
  - Public Hearing
  - Decision

- XI. Calcium Channel Blocker Agents (Non-Dihydropyridines)**
  - Discussion
  - Public Hearing
  - Decision
- XII. Direct Renin Inhibitors and Combination Agents**
  - Discussion
  - Public Hearing
  - Decision
- XIII. Hepatitis C Therapy: Direct-Acting Antiviral Agents**
  - Discussion
  - Public Hearing
  - Decision
- XIV. Homozygous Familial Hypercholesterolemia Products**
  - Discussion
  - Public Hearing
  - Decision
- XV. Lipotropic Agents: Niacin and Combination Preparations**
  - Discussion
  - Public Hearing
  - Decision
- XVI. Lipotropic Agents: Statins (HMG Co-A Reductase Inhibitors) and Statin Combination Products**
  - Discussion
  - Public Hearing
  - Decision
- XVII. Proton Pump Inhibitor Agents**
  - Discussion
  - Public Hearing
  - Decision
- XVIII. Pulmonary Hypertension Agents: Inhaled/Injectable**
  - Discussion
  - Public Hearing
  - Decision
- XIX. Pulmonary Hypertension Agents: Oral**
  - Discussion
  - Public Hearing
  - Decision
- XX. Sympatholytic Antihypertensive Agents**
  - Discussion
  - Public Hearing
  - Decision

**XXI. Triglyceride Lowering Agents**

- Discussion
- Public Hearing
- Decision

**E. Preferred Drug List Classes for Dec/Jan**

- i. Process Discussion
- ii. Therapeutic classes/to be announced at meeting

1:00

**LUNCH**

1:15-1:30

**Program Utilization Information-Xerox Update**

Luke Boehmer

1:30-1:50

**Other Business**

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

*Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly*

**NEXT MEETING: December 15, 2016**

**Department of Natural Resources - 1101 Riverside Dr.**

**Lacharrette/Nightengale Rooms**